LENZ Therapeutics (LENZ) Receivables (2025 - 2026)
LENZ Therapeutics (LENZ) reported Receivables of $343000.0 for Q1 2026, up 4.26% quarter-over-quarter from $329000.0 in Q4 2025.
LENZ Therapeutics (LENZ) Receivables (2025 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has 2 years of Receivables data on file, last reported at $343000.0 in Q1 2026.
- Receivables for Q1 2026 came in at $343000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $343000.0 (changed N/A YoY), and the FY2025 annual result was $329000.0, changed N/A from the prior year.
- Receivables rose to $343000.0 in Q1 2026 per LENZ's latest filing, from $329000.0 in the prior quarter.
- Over five years, Receivables peaked at $343000.0 in Q1 2026 and troughed at $329000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 13.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 2.00 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | LENZ Therapeutics | 192.19 Mn | 192.19 Mn | 825,000.00 | 343,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 343,000.00 |
| Dec 31, 2025 | 329,000.00 |